Table 3 Univariate and multivariate analysis results for overall survival and event-free survival; MRI group

Clinicopathological features

 Sex (female)

0.369(0.134–1.011)

0.052

0.545(0.234–1.265)

0.158

 Age(> 60)

1.347(0.572–3.172)

0.496

1.555(0.707–3.416)

0.272

 CEA

2.084(0.861–5.044)

0.103

1.773(0.776–4.052)

0.174

 CA199

2.841(1.141–7.074)

0.025

1.633(0.619–4.311)

0.322

2.917(1.253–6.789)

0.013

1.589(0.625–4.035)

0.331

 Tumor necrosis

1.998(0.729–5.482)

0.179

1.382(0.516–3.699)

0.520

Imaging features

 Size (> 5 cm)

2.298(0.963–5.483)

0.061

1.900(0.861–4.195)

0.112

 Tumour multiplicity

8.762(2.94–26.094)

 < 0.001

6.524(2.108–20.193)

0.001

4.241(1.675–10.734)

0.002

2.708(1.017–7.208)

0.046

 Lesion contour (infiltrative)

1.365(0.550–3.390)

0.502

1.143(0.492–2.658)

0.755

 Tumor location (perihilar)

0.705(0.095–5.261)

0.733

1.019(0.235–4.410)

0.980

 Cirrhosis

1.740(0.511–5.928)

0.376

2.500(0.837–7.469)

0.101

Vascular invasion

2.046(0.687–6.095)

0.198

2.371(0.884–6.356)

0.086

 Lymph node metastasis

2.376(0.863–6.541)

0.094

2.216(0.846–5.344)

0.109

 Bile duct invasion

1.100(0.402–3.004)

0.853

1.808(0.775–4.216)

0.171

 Arterial enhancement pattern

0.018

0.026

0.012

0.027

 Hypoenhancement(vs. hyper)

6.644(1.787–24.697)

0.005

6.024(1.605–22.613)

0.008

5.746(1.809–18.249)

0.003

4.971(1.535–16.091)

0.007

 Rim-enhancement(vs. hyper)

4.582(1.237–16.978)

0.023

3.240(0.839–12.501)

0.088

4.042(1.262–12.938)

0.019

2.986(0.879–10.152)

0.080

 DWI pattern (< 1/3 vs. > 1/3)

0.439(0.125–1.543)

0.199

0.398(0.112–1.416)

0.155

 HBP SI pattern (intermediate vs. hypointense)

1.480(0.477–4.592)

0.498

1.382(0.445–4.294)

0.576

 Enhancing capsule

1.435(0.333–6.177)

0.628

1.045(0.245–4.453)

0.952

 Delayed enhancement

1.098(0.443–2.722)

0.840

1.564(0.691–3.542)

0.284